Vaxcyte, Inc. (PCVX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Carlos, CA, 미국. 현재 CEO는 Grant E. Pickering.
PCVX 을(를) 보유 IPO 날짜 2020-06-12, 414 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $9.03B.
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines to prevent and treat bacterial infectious diseases. The company's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for invasive pneumococcal disease and pneumonia. Vaxcyte's pipeline also includes VAX-XP to address emerging strains and antibiotic resistance, VAX-A1 targeting Group A Strep, and VAX-PG designed to treat periodontitis. Founded in 2013 and headquartered in San Carlos, California, the company was formerly known as SutroVax, Inc. before rebranding in May 2020.
